Epigenetic studies in rhabdomyosarcoma
Epigenetic studies in rhabdomyosarcoma
批准号:
9153908
负责人:
Frederic Barr
金额:
$43.38万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
AlgorithmsBiological AssayBone MarrowCategoriesCell Culture TechniquesCell LineChildhoodChromatinCollectionDNA MethylationDNA Methyltransferase InhibitorDataDeoxycytidineDevelopmentDiagnosticEMILIN1 geneEpigenetic ProcessEventFamilyGenesGenetic TranscriptionGenomic DNAGoalsHuman GenomeHypermethylationMalignant NeoplasmsMessenger RNAMethylationModelingNormal tissue morphologyNucleic Acid Regulatory SequencesPAX3 genePAX7 genePoint MutationPrincipal Component AnalysisRecurrenceReverse Transcriptase Polymerase Chain ReactionRhabdomyosarcomaSamplingSiteSkeletal MuscleSkeletal boneTissue SampleTissue-Specific Gene Expressionbasebead chipbisulfitecohortgenome wide methylationgenome-wideinhibitor/antagonistmRNA Expressionpromoterpyrosequencingsoft tissuetumor
中文摘要
该项目的直接目标是研究融合阳性和融合阴性横纹肌肉瘤(RMS)肿瘤之间DNA甲基化的差异。在之前的研究中,我们使用Illumina甲基化阵列检测了20个融合阳性和17个融合阴性RMS样本中的DNA甲基化。无监督的层次聚类和主成分分析表明,RMS肿瘤聚集成两组融合阳性或融合阴性的情况下组成。我们还在一组5个融合阳性和5个融合阴性RMS细胞系中发现了类似的聚类。监督分析鉴定了与融合阴性RMS肿瘤相比,融合阳性RMS肿瘤中显著高甲基化的探针和显著低甲基化的其他探针。为了研究在融合阳性或融合阴性的RMS中是否存在甲基化差异,我们比较了RMS与两种正常组织(骨骼肌和骨髓)的甲基化。使用两种RMS亚型之间差异甲基化的CpG位点,分层聚类显示正常组织样品紧密聚类,并且与融合阴性RMS样品一起分组在一个主分支上,而所有融合阳性样品在另一个主分支上。尽管许多差异甲基化位点的甲基化状态在融合阴性肿瘤和正常组织中是相似的,但也有差异甲基化位点,其在融合阳性肿瘤中的甲基化状态与任一或两种正常组织非常相似。这些甲基化研究显示了两种融合亚型与正常组织不同基因组的相似性,我们提出融合阳性肿瘤中存在“异常”低甲基化和高甲基化事件,而融合阴性肿瘤中存在其他“异常”高甲基化和低甲基化事件。为了进一步研究甲基化和表达之间的关系,我们用DNA甲基转移酶抑制剂5-氮杂-2 '-脱氧胞苷(aza-dC)处理了6个融合阳性和5个融合阴性RMS细胞系。我们专注于EMILIN 1基因,并使用焦磷酸测序在6个对照处理的融合阳性细胞系中的5个和5个对照处理的融合阴性细胞系中的仅1个中发现非常高(80%)的DNA甲基化水平。aza-dC处理后,在1个融合阴性和5个融合阳性细胞系中,EMILIN 1启动子甲基化水平显著降低。定量RT-PCR分析表明,对照处理的EMILIN 1 mRNA水平非常低,而aza-dC处理的相同1个融合阴性和5个融合阳性细胞系的mRNA水平显著增加。这些发现表明,EMILIN 1启动子甲基化和表达呈负相关,甲基化缺失导致EMILIN 1 mRNA表达增加。
英文摘要
The immediate goal of this project was to investigate differences in DNA methylation between fusion-positive and fusion-negative rhabdomyosarcoma (RMS) tumors. In previous studies, we used Illumina methylation arrays to examine DNA methylation in 20 fusion-positive and 17 fusion-negative RMS samples. Unsupervised hierarchical clustering and principal component analyses showed that the RMS tumors clustered into two groups consisting exclusively of fusion-positive or fusion-negative cases. We also found a similar clustering in a panel of 5 fusion-positive and 5 fusion-negative RMS cell lines. A supervised analysis identified probes that were significantly hypermethylated and other probes that were significantly hypomethylated in fusion-positive compared to fusion-negative RMS tumors. To investigate whether any methylation difference represents an "aberrant" event in fusion-positive or fusion-negative RMS, we compared methylation in RMS with two normal tissues, skeletal muscle and bone marrow. Using the CpG sites that are differentially methylated between the two RMS subtypes, hierarchical clustering revealed that the normal tissue samples were tightly clustered, and were grouped together on one main branch with the fusion-negative RMS samples while all fusion-positive samples were on the other main branch. Though the methylation status of numerous differentially methylated sites is similar in fusion-negative tumors and the normal tissues, there are also differentially methylated sites for which the methylation status in fusion-positive tumors closely resembles either or both normal tissues. These methylation studies show similarities of both fusion subtypes to normal tissues for different sets of genes, and we propose that there are "aberrant" hypo- and hypermethylation events occurring in fusion-positive tumors, and other "aberrant" hyper- and hypomethylation events occurring in fusion-negative tumors. To further examine the relationship between methylation and expression, we treated 6 fusion-positive and 5 fusion-negative RMS lines with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine (aza-dC). We focused on the EMILIN1 gene and used pyrosequencing to find very high (80%) DNA methylation levels in 5 of 6 control-treated fusion-positive lines and only 1 of 5 control-treated fusion-negative lines. After aza-dC treatment, there was a significant decrease in EMILIN1 promoter methylation levels in the 1 fusion negative and 5 fusion-positive lines. Quantitative RT-PCR analysis showed that there are very low EMILIN1 mRNA levels with control treatment and significantly increased mRNA levels with aza-dC treatment of the same 1 fusion negative and 5 fusion-positive lines. These findings indicate that EMILIN1 promoter methylation and expression are inversely correlated, and that loss of methylation results in increased EMILIN1 mRNA expression.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Studies of gene fusions in rhabdomyosarcoma
-
批准号:10486830
-
项目类别:
-
资助金额:$70.45万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Studies of amplification in rhabdomyosarcoma
-
批准号:8349507
-
项目类别:
-
资助金额:$17.03万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Studies of amplification in rhabdomyosarcoma
-
批准号:8763479
-
项目类别:
-
资助金额:$33.5万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Clinical Operations for Laboratory of Pathology
-
批准号:9556867
-
项目类别:
-
资助金额:$66.83万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Studies of gene fusions in rhabdomyosarcoma
-
批准号:9153887
-
项目类别:
-
资助金额:$47.33万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Studies of gene fusions in rhabdomyosarcoma
-
批准号:8763485
-
项目类别:
-
资助金额:$40.2万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Studies of amplification in rhabdomyosarcoma
-
批准号:9556544
-
项目类别:
-
资助金额:$30.47万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Studies of gene fusions in rhabdomyosarcoma
-
批准号:9343899
-
项目类别:
-
资助金额:$59.23万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Epigenetic studies in rhabdomyosarcoma
-
批准号:8553174
-
项目类别:
-
资助金额:$51.06万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Epigenetic studies in rhabdomyosarcoma
-
批准号:8938110
-
项目类别:
-
资助金额:$50.65万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Studies of amplification in rhabdomyosarcoma
-
批准号:8938081
-
项目类别:
-
资助金额:$41.07万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Anatomic Pathology Residency Program
-
批准号:10703126
-
项目类别:
-
资助金额:$203.96万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Anatomic Pathology Residency Program
-
批准号:9556893
-
项目类别:
-
资助金额:$152.37万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Studies of amplification in rhabdomyosarcoma
-
批准号:10926196
-
项目类别:
-
资助金额:$74.45万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Epigenetic studies in rhabdomyosarcoma
-
批准号:10014672
-
项目类别:
-
资助金额:$30.76万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Studies of amplification in rhabdomyosarcoma
-
批准号:9343894
-
项目类别:
-
资助金额:$29.61万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Studies of amplification in rhabdomyosarcoma
-
批准号:10486826
-
项目类别:
-
资助金额:$54.79万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Epigenetic studies in rhabdomyosarcoma
-
批准号:10486842
-
项目类别:
-
资助金额:$39.14万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Studies of gene fusions in rhabdomyosarcoma
-
批准号:8349513
-
项目类别:
-
资助金额:$17.03万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Epigenetic studies in rhabdomyosarcoma
-
批准号:8763513
-
项目类别:
-
资助金额:$37.97万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
海外基金